Detalhe da pesquisa
1.
High transferrin saturation predicts inferior clinical outcomes in patients with myelodysplastic syndromes.
Haematologica
; 108(2): 532-542, 2023 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35979720
2.
Patient-reported fatigue refines prognosis in higher-risk myelodysplastic syndromes (MDS): a MDS-CAN study.
Br J Haematol
; 194(2): 319-324, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34060069
3.
Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis.
Br J Haematol
; 179(1): 83-97, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28677895
4.
A predictive model of response to erythropoietin stimulating agents in myelodysplastic syndrome: from the Canadian MDS patient registry.
Ann Hematol
; 96(12): 2025-2029, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-28975386
5.
Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective study.
Br J Haematol
; 174(1): 88-101, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-26991631
6.
BCL-2 inhibitors sensitize therapy-resistant chronic lymphocytic leukemia cells to VSV oncolysis.
Mol Ther
; 21(7): 1413-23, 2013 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-23689597
7.
A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the MDS-CAN registry.
Leuk Lymphoma
; 63(13): 3165-3174, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36095125
8.
VSV oncolysis in combination with the BCL-2 inhibitor obatoclax overcomes apoptosis resistance in chronic lymphocytic leukemia.
Mol Ther
; 18(12): 2094-103, 2010 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-20842105
9.
Targeting the apoptotic pathway with BCL-2 inhibitors sensitizes primary chronic lymphocytic leukemia cells to vesicular stomatitis virus-induced oncolysis.
J Virol
; 82(17): 8487-99, 2008 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-18579592
10.
Iron overload in myelodysplastic syndromes: Evidence based guidelines from the Canadian consortium on MDS.
Leuk Res
; 74: 21-41, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30286330
11.
Revised 15-item MDS-specific frailty scale maintains prognostic potential.
Leukemia
; 34(12): 3434-3438, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32855438
12.
The immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes: a clinical practice guideline.
Crit Rev Oncol Hematol
; 85(2): 162-92, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22901762